Omentin-1 vs CJC-1295
Head-to-head comparison of Omentin-1 (Omentin-1 (Intelectin-1, ITLN1)) and CJC-1295 (Growth Hormone Releasing Hormone Analog) — benefits, dosing, side effects, research data, and where to buy.
| Property | Omentin-1 | CJC-1295 |
|---|---|---|
| Category | Diabetes & Metabolic | Performance |
| Full Name | Omentin-1 (Intelectin-1, ITLN1) | Growth Hormone Releasing Hormone Analog |
| Molecular Weight | ~35 kDa | 3,367.97 Da |
| Half-Life | hours | ~6-8 days (DAC) |
| Amino Acids | 313 | 30 |
| Typical Dose | No approved human dose; research use only | 1-2 mg/week |
| Route | IV|SC | SC |
| Purity | ≥98% | — |
| Studies Count | 82 | 167 |
| Research Status | Pre-clinical | Clinical Trials |
Omentin-1 Benefits
- ✓insulin sensitivity
- ✓glucose uptake
- ✓lipid handling
CJC-1295 Benefits
- ✓Sustained GH release over days
- ✓Improved body composition
- ✓Enhanced deep sleep quality
- ✓Accelerated recovery from training
- ✓Increased protein synthesis
Omentin-1 Dosing
not established|not established
CJC-1295 Dosing
Without DAC: 100-200 mcg SC 2-3 times daily|With DAC: 1-2 mg SC once or twice weekly|Combined with Ipamorelin: 100 mcg each, 2-3x daily
Omentin-1 Side Effects
- ⚠unknown
- ⚠immunogenicity risk
CJC-1295 Side Effects
- ⚠Common (Mild): Water retention, tingling/numbness, flushing
- ⚠Moderate: Joint stiffness, carpal tunnel-like symptoms
- ⚠Rare: Elevated blood sugar (transient)
Research Overview
Omentin-1
Lower omentin-1 levels are often associated with obesity, insulin resistance, and metabolic syndrome. Research continues on its use as a biomarker and as a mechanistic lead for AMPK-linked metabolic interventions.
CJC-1295
CJC-1295 has good pre-clinical and early clinical data. The DAC variant shows sustained GH elevation for days. Often combined with GHRPs for synergistic GH release.
Ready to buy?
Find both peptides from our verified, lab-tested vendors with purity certificates and third-party testing.